Hypnion
Advancing neuroscience to enhance sleep and wake-alertness with innovative treatments for CNS disorders.
Advancing neuroscience to enhance sleep and wake-alertness with innovative treatments for CNS disorders.
Hypnion is a neuroscience-focused firm founded in 2000 and acquired by Eli Lilly and Company. The company's slogan "Advancing neuroscience to enhance sleep and wake-alertness with innovative treatments for CNS disorders," highlights its dedication to the discovery and development of new treatments for central nervous system disorders, particularly in addressing sleep and wake-alertness issues as well as circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform specifically designed to measure the impact of drugs on sleep and wake parameters. The company falls within the Biotechnology, Health Care, Health and Wellness industries and is headquartered in Worcester, Massachusetts. Its last investment was a $20.10M Series B investment on 19 December 2005, with participation from Jafco Ventures, MPM Capital, Advanced Technology Ventures, Flagship Pioneering, Forward Ventures, GIMV, Oxford Bioscience Partners, SR One, Mintz, Alexandria Real Estate Equities.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $20.10M | 10 |
|
19 Dec 2005 |
| Series B | $47.50M | - | 17 Mar 2003 | |
| Series A | $10.40M | - | 06 Oct 2000 |
No recent news or press coverage available for Hypnion.
We care about your data, and we'd love to use cookies make your experience better.